Heart-Kidney drug trial halted early – what happened?

NCT ID NCT06611423

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental drug called AZD3427 in 10 people with heart failure and reduced kidney function. The goal was to see if the drug could improve blood flow to the kidneys, measured with a special PET scan. However, the study was terminated early, so we don't have clear results on whether the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AZD3427

What this could lead to

If it worked, this could point toward a new way to protect kidney function in people with heart failure.

What could go wrong

This was a very small, early-phase trial that was terminated early, so we have little data. The drug may not improve kidney blood flow or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Solna, 171 64, Sweden